Socié G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009 Nov 12. 114(20):4327-36. [QxMD MEDLINE Link]. [Full Text].
Burt RK, Hess A, Deeg HJ. How to identify GVHD. Contemp Oncol. 1993. 19-34.
Atkinson K. Chronic graft-versus-host disease. Bone Marrow Transplant. 1990 Feb. 5(2):69-82. [QxMD MEDLINE Link].
Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, et al. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Hematologica. september 2011. 96:1351-1356. [QxMD MEDLINE Link].
Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Apr. 11(4):307-13. [QxMD MEDLINE Link].
Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, et al. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Sep. 15 (9):1116-21. [QxMD MEDLINE Link].
Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. February 15, 2008. 111:2470-2475. [QxMD MEDLINE Link].
Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016 Dec 22. 128 (25):2899-2908. [QxMD MEDLINE Link]. [Full Text].
Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017 Nov 23. 130 (21):2243-2250. [QxMD MEDLINE Link]. [Full Text].
Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15. 108(2):756-62. [QxMD MEDLINE Link].
Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006 Apr 15. 107(8):3074-80. [QxMD MEDLINE Link].
Gandelman JS, Song DJ, Chen H, Engelhardt BG, Chen YB, Clark WB, et al. A Prospective Trial of Extracorporeal Photopheresis for Chronic Graft-versus-Host Disease Reveals Significant Disease Response and No Association with Frequency of Regulatory T Cells. Biol Blood Marrow Transplant. 2018 Dec. 24 (12):2373-2380. [QxMD MEDLINE Link].
BARNES DW, LOUTIT JF, MICKLEM HS. "Secondary disease" of radiation chimeras: a syndrome due to lymphoid aplasia. Ann N Y Acad Sci. 1962 Oct 24. 99:374-85. [QxMD MEDLINE Link].
Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966-1967. 62:21-78. [QxMD MEDLINE Link].
Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991 Mar 7. 324(10):667-74. [QxMD MEDLINE Link].
Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992 Dec 15. 80(12):2964-8. [QxMD MEDLINE Link].
Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009 Dec 3. 114(24):4919-27. [QxMD MEDLINE Link].
Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A. Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood. 2010 Mar 18. 115(11):2319-28. [QxMD MEDLINE Link].
Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B, et al. Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2010 Apr 15. 115(15):3162-5. [QxMD MEDLINE Link]. [Full Text].
Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol. 2010 Apr. 11(4):331-8. [QxMD MEDLINE Link].
Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990 Jun 15. 75(12):2459-64. [QxMD MEDLINE Link].
Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 1. 102(5):1601-5. [QxMD MEDLINE Link].
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009 Sep. 10(9):855-64. [QxMD MEDLINE Link].
Shimabukuro-Vornhagen A, Liebig T, von Bergwelt-Baildon M. Statins inhibit human APC function: implications for the treatment of GVHD. Blood. 2008 Aug 15. 112(4):1544-5. [QxMD MEDLINE Link].
Petersdorf EW. Genetics of graft-versus-host disease: The major histocompatibility complex. Blood Rev. 2012 Nov 19. [QxMD MEDLINE Link].
Rotta M, Storer BE, Storb RF, Martin PJ, Heimfeld S, Peffer A, et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood. 2010 Feb 11. 115(6):1288-95. [QxMD MEDLINE Link]. [Full Text].
Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003 Jul 15. 102(2):756-62. [QxMD MEDLINE Link].
Miller KB, Roberts TF, Chan G, et al. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant. 2004 May. 33(9):881-9. [QxMD MEDLINE Link].
Ferrara JLM, Antin JH. The Pathophysiology of Graft-versus-Host Disease. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. 5th ed. Boston, Ma: Wiley-Blackwell; 2016. 146-52.
Deeg HJ, Henslee-Downey PJ. Management of acute graft-versus-host disease. Bone Marrow Transplant. 1990 Jul. 6(1):1-8. [QxMD MEDLINE Link].
Oehler VG, Radich JP, Storer B, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant. 2005 Feb. 11(2):85-92. [QxMD MEDLINE Link].
Schmitz N, Beksac M, Bacigalupo A, et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica. 2005 May. 90(5):643-8. [QxMD MEDLINE Link].
Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007 Feb 1. 109(3):1322-30. [QxMD MEDLINE Link].
Sung AD, Hassan S, Cardona DM, Wild D, Nichols KR, Mehdikhani H, et al. Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults. Biol Blood Marrow Transplant. 2018 Apr. 24 (4):734-740. [QxMD MEDLINE Link].
Jacobsohn DA, Chan GW, Chen AR. Current Advances in the Treatment of Acute and Chronic Graft-versus-Host Disease. Blood and Marrow Transplantation Reviews. Feb 7, 2007. 17(4):4-14.
Song I, Yi CA, Han J, Kim DH, Lee KS, Kim TS, et al. CT findings of late-onset noninfectious pulmonary complications in patients with pathologically proven graft-versus-host disease after allogeneic stem cell transplant. AJR Am J Roentgenol. 2012 Sep. 199(3):581-7. [QxMD MEDLINE Link].
Pathak M, Diep PP, Lai X, Brinch L, Ruud E, Drolsum L. Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation. Bone Marrow Transplant. 2018 Jul. 53 (7):863-872. [QxMD MEDLINE Link]. [Full Text].
McDonald GB, Sullivan KM, Plumley TF. Radiographic features of esophageal involvement in chronic graft-vs.-host disease. AJR Am J Roentgenol. 1984 Mar. 142 (3):501-6. [QxMD MEDLINE Link]. [Full Text].
Behar E, Chao NJ, Hiraki DD, et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med. 1996 Feb 1. 334(5):286-91. [QxMD MEDLINE Link].
Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003 Dec 4. 349(23):2201-10. [QxMD MEDLINE Link].
Reddy V, Iturraspe JA, Tzolas AC, et al. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood. 2004 Jun 1. 103(11):4330-5. [QxMD MEDLINE Link].
Paczesny S. Biomarkers for posttransplantation outcomes. Blood. 2018 May 17. 131 (20):2193-2204. [QxMD MEDLINE Link]. [Full Text].
Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009 Jan 8. 113(2):273-8. [QxMD MEDLINE Link]. [Full Text].
Fiema B, Harris AC, Gomez A, Pongtornpipat P, Lamiman K, Vander Lugt MT, et al. High throughput sequential ELISA for validation of biomarkers of acute graft-versus-host disease. J Vis Exp. 2012 Oct 31. [QxMD MEDLINE Link]. [Full Text].
Budde H, Papert S, Maas JH, Reichardt HM, Wulf G, Hasenkamp J, et al. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines. Ann Hematol. 2017 Jul. 96 (7):1127-1133. [QxMD MEDLINE Link].
Min SS, Mehra V, Clay J, Cross GF, Douiri A, Dew T, et al. Composite biomarker panel for prediction of severity and diagnosis of acute GVHD with T-cell-depleted allogeneic stem cell transplants-single centre pilot study. J Clin Pathol. 2017 Oct. 70 (10):886-890. [QxMD MEDLINE Link].
Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013 Aug 8. 369(6):529-39. [QxMD MEDLINE Link].
Srinagesh HK, Levine JE, Ferrara JLM. Biomarkers in acute graft-versus-host disease: new insights. Ther Adv Hematol. 2019. 10:2040620719891358. [QxMD MEDLINE Link]. [Full Text].
Salas MQ, Ezzat S, Lam W, Law AD, Pasic I, Michelis FV, et al. Prolactin, a potential biomarker for chronic GVHD activity. Eur J Haematol. 2021 Feb. 106 (2):158-164. [QxMD MEDLINE Link].
Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998 Oct 1. 92(7):2303-14. [QxMD MEDLINE Link].
Mollee P, Morton AJ, Irving I, et al. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. Br J Haematol. 2001 Apr. 113(1):217-23. [QxMD MEDLINE Link].
Kröger N, Solano C, Wolschke C, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016 Jan 7. 374 (1):43-53. [QxMD MEDLINE Link].
Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000 Oct 1. 96(7):2419-25. [QxMD MEDLINE Link].
Mielcarek M, Furlong T, O'Donnell PV, Storer BE, McCune JS, Storb R, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016 Mar 17. 127 (11):1502-8. [QxMD MEDLINE Link].
Choi SW, Braun T, Henig I, Gatza E, Magenau J, Parkin B, et al. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017 Oct 12. 130 (15):1760-1767. [QxMD MEDLINE Link]. [Full Text].
Khandelwal P, Yeh RF, Yu L, Lane A, Dandoy CE, El-Bietar J, et al. Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa. Transplantation. 2021 Apr 1. 105 (4):891-896. [QxMD MEDLINE Link].
Hoda D1, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone marrow transplant. August 2010. 45:1347-1351. [QxMD MEDLINE Link].
Ferrara JL, Yanik G. Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies. Clin Adv Hematol Oncol. 2005 May. 3(5):415-9, 428. [QxMD MEDLINE Link].
Shapiro RM, Antin JH. Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape. Expert Rev Hematol. 2020 May. 13 (5):519-532. [QxMD MEDLINE Link].
Zeiser R, Burchert A, Lengerke C, Verbeek M, von Bubnoff N. et.al. Ruxolitinib in corticosteroidrefractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey. Leukemia. october 1, 2015. 29:2062-2068. [QxMD MEDLINE Link].
Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy. 2018 Apr. 10 (5):391-402. [QxMD MEDLINE Link]. [Full Text].
Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008 Feb 15. 111(4):2470-5. [QxMD MEDLINE Link]. [Full Text].
Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009 Jul 16. 114(3):511-7. [QxMD MEDLINE Link]. [Full Text].
Deeg HJ, Blazar BR, Bolwell BJ, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001 Oct 1. 98(7):2052-8. [QxMD MEDLINE Link].
Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Jun. 11 (6):465-71. [QxMD MEDLINE Link].
Alam N, Atenafu EG, Tse G, Viswabandya A, Gupta V, Kim D, et al. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease. Clin Transplant. 2013 Nov-Dec. 27 (6):930-7. [QxMD MEDLINE Link].
Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015 Jan 22. 125 (4):606-15. [QxMD MEDLINE Link]. [Full Text].
Nick Mulchahy. FDA Approves First-of-Its-Kind Drug for Chronic Graft-Versus-Host Disease. Medscape. Available at https://www.medscape.com/viewarticle/954986. July 29, 2021; Accessed: August 10,2021.
Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009 Jul 16. 114(3):709-18. [QxMD MEDLINE Link].
FDA approves ruxolitinib for chronic graft-versus-host disease. U.S. Food & Drug Administration. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-chronic-graft-versus-host-disease. September 22, 2021; Accessed: September 23, 2021.
Vogelsang GB, Wolff D, Altomonte V, Farmer E, Morison WL, Corio R, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant. 1996 Jun. 17 (6):1061-7. [QxMD MEDLINE Link].
CDC. Centers for Disease Control and Prevention. Infectious Diseases Society of America. American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2000. 6(6a):659-713; 715; 717-27; quiz 729-33. [QxMD MEDLINE Link].
Morishima S, Kashiwase K, Matsuo K, Azuma F, Yabe T, Sato-Otsubo A, et al. High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation. Haematologica. 2016 Apr. 101 (4):491-8. [QxMD MEDLINE Link].
Bolaños-Meade J, Reshef R, Fraser R, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019 Mar. 6 (3):e132-e143. [QxMD MEDLINE Link].
Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant. 1996 Feb. 2 (1):44-53. [QxMD MEDLINE Link].
